Balanced news tone
News Sentiment
PGEN sentiment intelligence
Precigen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-7.0% over one week, +2.7% over four weeks, trend active, and materially above fair value.
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
H.C. Wainwright Remains a Buy on Precigen (PGEN)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Market source
Precigen Wins FDA Orphan Drug Exclusivity for Airway Disease Treatment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 11:36
- Source
- MT Newswires
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 15 Jun 2026 10:40
- Source
- ACCESS Newswire
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jun 2026 07:00
- Source
- Market source
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- The Motley Fool
Have Precigen Insiders Been Selling Stock?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- simplywall.st
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Market source
Precigen chief legal officer Lehr sells $127,011 in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Investing.com
Precigen (PGEN) CFO gains 87,500 shares from RSU vesting
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Stock Titan
Precigen (PGEN): The Best Penny Stock to Buy for Long Term
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Market source
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 16 May 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Precigen Reports First Quarter 2026 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- PR Newswire
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
May 13 at 4:30 ET: Precigen pairs Q1 results with business update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Apr 2026 07:00
- Source
- Market source
Wall Street Bullish on Precigen (PGEN) As the Company Transitions to Commercial Stage
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 12 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Mar 2026 07:00
- Source
- Market source
Precigen Reports Full Year 2025 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Mar 2026 07:00
- Source
- PR Newswire
Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- simplywall.st
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- simplywall.st
First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen?
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 24 Aug 2025 07:00
- Source
- MedCity News
Precigen shares jump after US FDA approves first therapy for rare respiratory disease
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Aug 2025 07:00
- Source
- Reuters